Search Results
290 results
Your search is now limited to «Amgen» expert search.
Drugs.com 01/21/2019 15:01
About the Amgen and UCB Collaboration Since 2004, Amgen and UCB have been working together under a collaboration and license agreement to research, develop and market antibody products targeting the protein sclerostin.
More from Drugs.com:
Zacks.com 01/21/2019 10:10
For the last reported quarter, Amgen came out with earnings of $3.69 per share versus the Zacks Consensus Estimate of $3.42 per share, representing a surprise of 7.89.
More from Zacks.com:
NASDAQ 01/18/2019 19:40
In the latest trading session Amgen AMGN closed at 203 70 marking a 0 88 move from the previous day The stock lagged the S amp P 500 s daily gain of 1 32 Meanwhile the Dow gained 1 38 and the Nasdaq a tech heavy index added 1 74 Heading into today shares of the world s.
More from NASDAQ:
Investor's Business Daily 01/17/2019 16:06
A Food and Drug Administration committee voted late Wednesday to recommend Amgen's (AMGN) osteoporosis treatment — but only to a narrowed population of postmenopausal women.
More from Investor's Business Daily:
Benzinga 01/17/2019 08:06
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak. (Biotech stocks hitting 52-week highs on Jan. 16). Avenue Therapeutics Inc (NASDAQ: ATXI ). BioDelivery Sciences International, Inc. (NASDAQ: BDSI ). ResMed Inc. (NYSE: RMD ). Down In The Dumps. (Biotech stocks hitting 52-week lows on Jan. 16). Amneal Pharmaceuticals Inc (NYSE: AMRX ). Aptinyx Inc (NASDAQ: APTX )(reported a mid-stage trial that evaluated NYX-2925, its treatment candidate for patients with painful diabetic peripheral neuropathy, did not meet the primary endpoint). Bio-Path Holdings Inc (NASDAQ: BPTH ). Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) (short seller Citron Research said there is likely to be 80-percent downside in the stock fr.
More from Benzinga:
ENDPOINTS 01/17/2019 07:02
Looks like Amgen and UCB’s osteoporosis drug is headed to the finish line, after an FDA panel largely supported its approval on Wednesday.
More from ENDPOINTS:
WN.com 01/16/2019 19:11
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies.
More from WN.com:
Xconomy 01/16/2019 18:29
Xconomy National — An experimental Amgen osteoporosis drug that had sparked concern about cardiovascular side effects has won the backing of an FDA advisory panel.
More from Xconomy:
Reuters.com 01/16/2019 17:58
Amgen's postmenopausal osteoporosis drug wins FDA panel backing.
More from Reuters.com:
FiercePharmaMarketing 01/16/2019 17:54
If you thought Amgen osteoporosis candidate Evenity (romosozumab) was down for the count, think again.
More from FiercePharmaMarketing:
Seeking Alpha 01/14/2019 10:26
Amgen produced almost $23 billion in sales last year.
More from Seeking Alpha:
PR Newswire 01/14/2019 07:30
The AmMag SA, developed under an exclusive license agreement with Amgen, combines the speed and high binding capacity of magnetic beads with high throughput for larger sample volumes, enabling researchers for the first time to purify up to 50 ml samples while maintaining a low endotoxin ...
More from PR Newswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications